CJC-1295 With DAC 5mg Research Peptide
CJC-1295 With DAC (Drug Affinity Complex) is a modified GHRH analogue engineered for markedly extended half-life through covalent binding to endogenous albumin via the DAC technology — a maleimidoproprionic acid (MPA) linker that reacts with a cysteine residue on circulating albumin. This albumin binding extends the half-life from approximately 30 minutes (CJC-1295 Without DAC / Modified GRF 1-29) to approximately 6–8 days, producing sustained GH elevation rather than discrete pulses. This 5mg vial provides research-grade CJC-1295 With DAC at ≥99% purity, HPLC and MS/MS verified per batch.
Research Background
CJC-1295 With DAC was specifically designed to test whether prolonged, sustained GH elevation produces different research outcomes than pulsatile GH stimulation. Published Phase 1 and Phase 2 data demonstrated dose-dependent GH and IGF-1 elevation lasting 6+ days following a single injection, with a pharmacokinetic profile closely resembling that of exogenous GH administration but via endogenous GH secretion from the pituitary. This extended-release profile makes it mechanistically distinct from all other GHRH analogues and useful for research protocols requiring sustained GH elevation without frequent dosing.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 5mg per vial
- Storage: −20°C, protected from light
- Half-life: ~6–8 days (albumin-bound)
- Molecular Weight: ~3647 Da (with DAC linker)
Certificate of Analysis
All CJC-1295 With DAC vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
